DekaBank Deutsche Girozentrale’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,000	Closed	-$108K	–	1507
2021 Q3	$108K	Hold	13,000	–	–	﹤0.01%	1295
2021 Q2	$211K	Hold	13,000	–	–	﹤0.01%	1207
2021 Q1	$278K	Hold	13,000	–	–	﹤0.01%	1129
2020 Q4	$397K	Buy	+13,000	New	+$329K	﹤0.01%	1069

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DekaBank Deutsche Girozentrale's TCRR Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 13,000 shares — an estimated $108K sold.

DekaBank Deutsche Girozentrale first reported a position in TCRR in Q4 2020 and held it in 4 quarters. The position peaked at $397K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 13,000 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $108K.
DekaBank Deutsche Girozentrale first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
DekaBank Deutsche Girozentrale's TCR2 Therapeutics Inc. Common Stock position peaked at $397K in Q4 2020.
122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.